Department of General Practice and Primary Care, University of Helsinki, Helsinki, Finland; Health Center, City of Vantaa, Finland.
Department of Obstetrics and Gynecology, University of Helsinki, Helsinki, Finland; Health Center, City of Vantaa, Finland.
Am J Obstet Gynecol. 2020 Dec;223(6):886.e1-886.e17. doi: 10.1016/j.ajog.2020.06.023. Epub 2020 Jun 17.
Since 2013, the residents of the city of Vantaa, Finland, have been offered their first long-acting reversible contraceptive method (levonorgestrel-releasing intrauterine system, implant, and copper intrauterine device) free of charge.
The primary aim of this study was to assess the 2-year cumulative discontinuation rates of long-acting reversible contraceptive methods when provided free of charge for first-time users in a real-world setting. Additional aims were to describe factors associated with discontinuation and to evaluate the reasons for discontinuation.
This is a retrospective register-based cohort study of 2026 nonsterilized women aged 15 to 44 years, who initiated a free-of-charge long-acting contraceptive method in 2013-2014 in the city of Vantaa. Removals within 2 years after method initiation and reasons for discontinuation were obtained from electronic health records and from national registers. We calculated the 2-year cumulative incidence rates of discontinuation with 95% confidence intervals for each method. Furthermore, we assessed crude and adjusted incidence rate ratios of discontinuation with 95% confidence interval by Poisson regression models comparing implants and copper intrauterine device with levonorgestrel-releasing intrauterine systems.
During the 2 -year follow-up, 514 women discontinued, yielding a cumulative discontinuation rate of 28.3 per 100 women-years (95% confidence interval, 26.2-30.4). Among the 1199 women who initiated the levonorgestrel-releasing intrauterine system, the cumulative discontinuation rate was 24.2 per 100 women-years (95% confidence interval, 21.7-26.9); among the 642 implant users, 33.3 per 100 women-years (95% confidence interval, 29.5-37.4); and among the 185 copper intrauterine device users, 37.8 per 100 women-years (95% confidence interval, 31.0-45.7). Compared with women aged 30 to 44 years, women aged 15 to 19 years (adjusted incidence rate ratio, 1.58; 95% confidence interval, 1.17-2.14) and 20 to 29 years (adjusted incidence rate ratio, 1.35; 95% confidence interval, 1.11-1.63) were more likely to discontinue. We observed a higher discontinuation rate in women who had given birth within the previous year (adjusted incidence rate ratio, 1.36; 95% confidence interval, 1.13-1.65), spoke a native language other than Finnish or Swedish (adjusted incidence rate ratio, 1.31; 95% confidence interval, 1.06-1.63), and had a history of a sexually transmitted infection (adjusted incidence rate ratio, 1.62; 95% confidence interval, 1.07-2.46). No association was found in marital status, overall parity, history of induced abortion, socioeconomic status, education level, or smoking status. The most common reason for discontinuation was bleeding disturbances, reported by 21% of women who discontinued the levonorgestrel-releasing intrauterine system, by 71% who discontinued the implant, and by 41% who discontinued the copper intrauterine device. One in 4 women who discontinued the copper intrauterine device reported heavy menstrual bleeding, whereas only 1% who discontinued the levonorgestrel-releasing intrauterine system and none who discontinued implants reported this reason. Abdominal pain was the reported reason for discontinuation in 20% of both intrauterine device users and in only 2% who discontinued implants.
At 2 years, the use of implants and copper intrauterine devices was more likely to be discontinued than that of the levonorgestrel-releasing intrauterine system. Women younger than 30 years and those who gave birth in the preceding year, spoke a native language other than Finnish or Swedish, or had a history of sexually transmitted infections were more likely to discontinue. The levonorgestrel-releasing intrauterine system was least likely to be removed owing to bleeding disturbances.
自 2013 年以来,芬兰万塔市的居民可免费获得他们的第一种长效可逆避孕方法(左炔诺孕酮宫内节育系统、植入物和铜宫内节育器)。
本研究的主要目的是评估在现实环境中,首次使用免费长效可逆避孕方法时,2 年累积停药率。其他目的是描述与停药相关的因素,并评估停药原因。
这是一项回顾性基于登记的队列研究,纳入了 2026 名年龄在 15 至 44 岁之间的未绝育女性,她们于 2013-2014 年在万塔市开始使用免费的长效可逆避孕方法。从电子健康记录和国家登记处获取方法启动后 2 年内的移除情况和停药原因。我们计算了每种方法的停药 2 年累积发生率及其 95%置信区间。此外,我们通过泊松回归模型评估了植入物和铜宫内节育器与左炔诺孕酮宫内节育系统相比的停药粗发病率比和调整发病率比及其 95%置信区间。
在 2 年的随访中,514 名女性停药,累积停药率为每 100 名女性年 28.3 例(95%置信区间,26.2-30.4)。在 1199 名开始使用左炔诺孕酮宫内节育系统的女性中,累积停药率为每 100 名女性年 24.2 例(95%置信区间,21.7-26.9);在 642 名植入物使用者中,每 100 名女性年 33.3 例(95%置信区间,29.5-37.4);在 185 名铜宫内节育器使用者中,每 100 名女性年 37.8 例(95%置信区间,31.0-45.7)。与 30-44 岁的女性相比,15-19 岁(调整发病率比,1.58;95%置信区间,1.17-2.14)和 20-29 岁(调整发病率比,1.35;95%置信区间,1.11-1.63)的女性更有可能停药。我们观察到,在过去一年中分娩过的女性(调整发病率比,1.36;95%置信区间,1.13-1.65)、母语非芬兰语或瑞典语的女性(调整发病率比,1.31;95%置信区间,1.06-1.63)和有性传播感染史的女性(调整发病率比,1.62;95%置信区间,1.07-2.46)的停药率更高。婚姻状况、总产次、人工流产史、社会经济地位、教育水平或吸烟状况与停药无关。最常见的停药原因是出血紊乱,报告称左炔诺孕酮宫内节育系统停药的女性中有 21%、植入物停药的女性中有 71%、铜宫内节育器停药的女性中有 41%。四分之一的铜宫内节育器停药的女性报告说月经过多,而只有 1%的左炔诺孕酮宫内节育器停药的女性和没有植入物停药的女性报告了这个原因。腹痛是宫内节育器使用者停药的原因之一,占 20%,而只有 2%的植入物停药的女性报告了腹痛。
2 年后,植入物和铜宫内节育器的使用率高于左炔诺孕酮宫内节育系统。30 岁以下的女性和在过去一年中分娩过、母语非芬兰语或瑞典语或有性传播感染史的女性更有可能停药。左炔诺孕酮宫内节育系统因出血紊乱而停药的可能性最小。